Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]
Awaiting development
Reference number: GID-TA11300
Expected publication date: TBC
Please note that following on from advice received from the company the timelines for this appraisal are to be confirmed. The appraisal will be scheduled to align with latest regulatory expectations and an update on the timelines will be provided when further information is available.